




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Remdesivir as a possible therapeutic option for the COVID-19

To the editor,

In a recent review article, there were multiple preventive measures that were proposed for the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [1]. Since 2002, we had witnessed the emergence of three coronaviruses with a significant impact. These are the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), MERS-CoV and the SARS-CoV-2, the causative agent of COVID-19. SARS-CoV-2 emerged in Wuhan, China, in December 2019, and according to the World Health Organization (WHO), the global number of confirmed cases was 80,239 as of February 25, 2020 [2]. However, there is no recommended therapy for any of these CoVs.

Remdesivir (with a development code GS-5734) is a broad-spectrum antiviral agent. This medication is an experimental drug and had not been licensed or approved at the time of writing this article. It was synthesized and developed by Gilead Sciences in 2017 as a treatment for Ebola virus infection. It is a monophosphoramidate prodrug and is an adenosine analog. Remdesivir is metabolized into its active form, GS-441524, that obscures viral RNA polymerase and evades proofreading by viral exonuclease, causing a decrease in viral RNA production. The antiviral mechanism of remdesivir is a delayed chain cessation of nascent viral RNA. Remdesivir showed antiviral activity against multiple variants of Ebola virus in cell-based assays [3] as well as in a rhesus monkey model of Ebola virus disease [4]. Remdesivir was given on a compassionate-use basis to a British nurse who initially survived Ebola virus disease and then she relapsed nine months later and had meningoencephalitis [5]. In a randomized controlled trial of Ebola Virus disease therapeutics, 673 participants received one of three monoclonal antibodies (Zmapp, mAb114 or REGN-EB3) or remdesivir [6]. However, the study was stopped as an interim analysis found that individuals who received REGN-EB3 or mAb114 had greater survival rates than either ZMapp or remdesivir [6].

In-vitro studies showed that remdesivir can inhibit coronaviruses such as SARS-CoV and MERS-CoV replication. In an in-vitro test utilizing epithelial cell cultures of a primary human airway, remdesivir was effective against Bat-CoVs, prepandemic Bat-CoVs, and circulating contemporary human-CoV in primary human lung cells [7,8]. One study showed that remdesivir and interferon beta were superior to lopinavir, ritonavir and interferon beta both *in vitro* and in a MERS-CoV mouse model [9].

With the emergence of the SARS-CoV-2, the etiologic agent of (COVID-19), we are in a need for an effective antiviral agent to be able to halt the current outbreak. It had been suggested that remdesivir might be an option for the therapy of patients with COVID-19 [10]. In a case report, remdesivir treatment was started intravenous on day 7 in a patient with COVID-19 [11]. Given the broad-spectrum anti-CoV activity of remdesivir that were demonstrated in pre-clinical studies; a

randomized, controlled, double blind clinical trial is planned to evaluate the efficacy and safety of remdesivir in hospitalized patients with mild or moderate COVID-19 respiratory disease [12] and this trial has already involved 308 hospitalized adult patients. The participants were randomized to either placebo or remdesivir arms (Remdesivir was given as 200 mg loading dose on day 1 followed by 100 mg iv once-daily for 9 days). The primary outcome was defined as the Time to Clinical recovery (TTCR), up to 28 days [12]. TTCR is further defined as the time (in hours) from initiation of study treatment (active or placebo) until normalization of fever, respiratory rate, and oxygen saturation, and alleviation of cough, sustained for at least 72 hours [12]. Another ongoing phase 3 randomized, double-blind, placebo-controlled, multicenter study is evaluating the efficacy and safety of remdesivir in 452 hospitalized adult patients with severe COVID-19 respiratory disease [13]. Any clinical impact of remdesivir on COVID-19 remains unknown, and scientists are waiting patiently the final results of these ongoing trials.

### Declaration of competing interest

All authors have no conflicts of interest.

### References

- [1] Baharoon S, Memish ZA. MERS-CoV as an emerging respiratory illness: a review of prevention methods. *Trav Med Infect Dis* 2019;32. <https://doi.org/10.1016/j.tmaid.2019.101520>.
- [2] World Health Organization. Situation Report-17 SITUATION IN NUMBERS total and new cases in last 24 hours. 2020 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200206-sitrep-17-ncov.pdf?sfvrsn=17f0dca\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200206-sitrep-17-ncov.pdf?sfvrsn=17f0dca_2), Accessed date: 7 February 2020.
- [3] Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature* 2016;531:381–5. <https://doi.org/10.1038/nature17180>.
- [4] Warren T, Jordan R, Lo M, Soloveva V, Ray A, Bannister R, et al. Nucleotide prodrug GS-5734 is a broad-spectrum filovirus inhibitor that provides complete therapeutic protection against the development of Ebola virus disease (EVD) in infected non-human primates. *Open Forum Infect Dis* 2015;2. <https://doi.org/10.1093/ofid/ofv130.02>.
- [5] Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe A, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. *Lancet* 2016;388:498–503. [https://doi.org/10.1016/S0140-6736\(16\)30386-5](https://doi.org/10.1016/S0140-6736(16)30386-5).
- [6] Mulangu S, Dodd LE, Davey RT, Mbaya OT, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. *N Engl J Med* 2019;381:2293–303. <https://doi.org/10.1056/NEJMoa1910993>.
- [7] Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exonuclease. *mBio* 2018;9. <https://doi.org/10.1128/mBio.00221-18>.
- [8] Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Sci Transl Med* 2017;9. <https://doi.org/10.1126/scitranslmed.aal3653>.
- [9] Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and

<https://doi.org/10.1016/j.tmaid.2020.101615>

Received 26 February 2020; Received in revised form 27 February 2020; Accepted 3 March 2020

Available online 05 March 2020

1477-8939/© 2020 Elsevier Ltd. All rights reserved.

interferon beta against MERS-CoV. Nat Commun 2020;11. <https://doi.org/10.1038/s41467-019-13940-6>.

- [10] Liu W, Morse JS, Lalonde T, Xu S. Learning from the past: possible urgent prevention and treatment options for severe Acute respiratory infections caused by 2019-nCoV. ChemBioChem 2020. <https://doi.org/10.1002/cbic.202000047>. cbic. 202000047.
- [11] Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020. <https://doi.org/10.1056/nejmoa2001191>.
- [12] Cao B. Mild/moderate 2019-nCoV remdesivir RCT - Full Text View - ClinicalTrials.gov. 2020<https://clinicaltrials.gov/ct2/show/NCT04252664>, Accessed date: 13 February 2020.
- [13] Cao B. Severe 2019-nCoV remdesivir RCT - Full Text View - ClinicalTrials.gov. 2020<https://clinicaltrials.gov/ct2/show/NCT04257656>, Accessed date: 13 February 2020.

Jaffar A. Al-Tawfiq\*

*Infectious Disease Unit, Specialty Internal Medicine and Infection Control Unit, Quality and Patient Safety, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia*

*Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA*

*Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA*

*E-mail addresses: [jaffar.tawfiq@jhah.com](mailto:jaffar.tawfiq@jhah.com), [jaltawfi@yahoo.com](mailto:jaltawfi@yahoo.com).*

*Ali H. Al-Homoud*

*Pharmacy Services Division, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia*

*Ziad A. Memish*

*Director Research Center, King Saud Medical City, Ministry of Health, Saudi Arabia*

*Al-Faisal University, Riyadh, Saudi Arabia*

*Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA*

\* Corresponding author. P.O. Box 76; Room A-428-2, Building 61, Dhahran Health Center, Johns Hopkins Aramco Healthcare, Dhahran, 31311, Saudi Arabia.